Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYWAY-RD: SPY002-072 in Rheumatologic Disease
NCT07148414Phase 2Active, not recruiting
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of SPY002 in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) (7 arms), sponsored by Spyre Therapeutics, Inc. Primary endpoints: Disease Activity Score in 28 joints (c-reactive protein) at 12 weeks, Ankylosing Spondylitis Disease Activity Score at 16 weeks and 1 more. Started Aug 2025; status: active, not recruiting.
02
Drugs
SPY002
03
Conditions
rheumatoid arthritis (RA)axial spondyloarthritis (axSpA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07148414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07148414.